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Abstract
Noninvasive functional imaging of tumors can provide valuable early-response biomarkers, in particular, for targeted
chemotherapy. Using various experimental tumor models, we have investigated the ability of positron emission to-
mography (PET) measurements of 2-deoxy-2-[18F]fluoro-glucose (FDG) and 3′-deoxy-3′-[18F]fluorothymidine (FLT) to
detect response to the allosteric mammalian target of rapamycin (mTOR) inhibitor everolimus. Tumor models were
declared sensitive (murine melanoma B16/BL6 and human lung H596) or relatively insensitive (human colon HCT116
and cervical KB31), according to the IC50 values (concentration inhibiting cell growth by 50%) for inhibition of prolif-
eration in vitro (<10 nM and>1 μM, respectively). Everolimus strongly inhibited growth of the sensitivemodels in vivo
but also significantly inhibited growth of the insensitive models, an effect attributable to its known anti–angiogenic/
vascular properties. However, although tumor FDG and FLT uptake was significantly reduced in the sensitive models,
it was not affected in the insensitive models, suggesting that endothelial-directed effects could not be detected by
these PET tracers. Consistent with this hypothesis, in a well-vascularized orthotopic rat mammary tumor model, other
antiangiogenic agents also failed to affect FDG uptake, despite inhibiting tumor growth. In contrast, the cytotoxic
patupilone, a microtubule stabilizer, blocked tumor growth, andmarkedly reduced FDG uptake. These results suggest
that FDG/FLT-PET may not be a suitable method for early markers of response to antiangiogenic agents and mTOR
inhibitors in which anti–angiogenic/vascular effects predominate because the method could provide false-negative
responses. These conclusions warrant clinical testing.
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Introduction
Everolimus (Afinitor; Novartis Pharma AG, Basel, Switzerland) is an
allosteric mammalian target of rapamycin (mTOR) inhibitor recently
approved for the treatment of second-line renal cell carcinoma. The pro-
tein mTOR is a multifunctional signal-transducing enzyme that func-
tions downstream of the phosphatidylinositol 3-kinase/AKT pathway
and influences the translation ofmany proteins known to be important
in cancer [1]. Inhibition of mTOR by everolimus and other derivatives
of rapamycin (rapalogs) results in tumor growth inhibition rather than
regression in preclinical models [2,3] and similar observations are
emerging in the clinic. For example, in the phase 3 registration trial in
renal cell carcinoma, the objective partial response rate was only 2%,
although there was a highly significant extension of the progression-
free survival compared with placebo [4], which translated into increased
survival despite crossover in the trial [5]. This trial clearly demonstrates
that merely quantifying tumor size can be an inadequate measurement
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of the activity of a targeted agent such as everolimus. Thus, the devel-
opment of more targeted agents in oncology mandates the application
of biomarkers that can help provide a reliable marker of response, as
well as identifying an optimal biologic dose (OBD), mechanism of ac-
tion (MoA), and the population to be treated. A number of different
approaches for these tasks are available, which include sampling of the
plasma, tumor biopsies, or functional imaging. The latter is particularly
attractive because, in principle, it allows repeated noninvasive imaging
of the whole target tissue rather than sampling of a heterogeneous
section. Several imaging methods are available, each of which provides
different advantages, and one that is becoming increasingly used is posi-
tron emission tomography (PET).
Various PETmethods may be used in oncology using radiotracers to
assess different aspects of tumor biology such as [15O]H2O for tumor
blood flow (TBF), 2-deoxy-2-[18F]fluoro-glucose (FDG) for glycolysis
and thus cell viability, 3′-deoxy-3′-[18F]fluorothymidine (FLT) for
S-phase and thus proliferation, and [18F]fluoromisonidazole (FMISO)
for hypoxia [6]. One of the consequences of mTOR inhibition is a re-
duction in levels of hypoxia-inducible factor 1 (HIF-1)[7], which causes
decreased levels of HIF-1 transcriptional targets including vascular
endothelial growth factor (VEGF), PDGF, glycolytic enzymes, and glu-
cose transporters. Other consequences of mTOR inhibition include re-
duced levels of the cyclins that drive the cell cycle, which results in aG1/S
block. In principle, therefore, an mTOR inhibitor should cause reduced
FDGand FLTuptake by tumors as well as reduced angiogenesis. Indeed,
in nonclinical models using everolimus, evidence of antiangiogenic ef-
fects have been recorded [2,7] along with a dose-dependent reduction of
FDG uptake [8]. Rapamycin has also been shown to reduce FDG and
FLTuptake both in vitro and in vivo in sensitive glioma cell lines but not
in a strongly resistant glioma model [9]. The most sensitive glioma cell
line, U87, showed reduced hexokinase activity and reduced thymidine
kinase expression after 24 hours of treatment with rapamycin [9], which
are the enzymes most likely governing uptake of FDG and FLT, respec-
tively [6]. Collectively, these data support the notion of imaging tumor
glucose and thymidine utilization for monitoring response to rapalogs
in the clinic. However, although some decreases in FDG uptake (6/8)
were detected in a non–small cell lung cancer (NSCLC) study for ever-
olimus [10], another report from phase 1/2 studies showed no correla-
tion between FDG changes and response to rapamycin in solid tumors
for 34 patients [11].
In this nonclinical study, we have investigated the effects of everoli-
mus on FDG and FLTuptake in human tumor xenografts derived from
cell lines characterized as sensitive or insensitive in vitro. We show that
in vivo, everolimus can inhibit growth of both types of tumor, which, in
these insensitive models, probably reflects the antiangiogenic activity of
the drug, but only the xenografts derived from sensitive cells showed
significant changes in FDG and FLTuptake. Consistent with these ob-
servations, other antiangiogenic compounds also failed to affect FDG
uptake, whereas a classic cytotoxic interfering with microtubule func-
tion caused a marked decrease in FDG uptake. These data suggest that
FDG/FLT-PETmay not always be a suitable marker of tumor response
because it could lead to a number of false-negatives for anticancer
agents whose primary MoA is antiangiogenic. Thus, although positive
PETresponses are always useful, negative PETresponses would, in these
cases, preclude PET being used to obtain an OBD.
Materials and Methods
All animal experiments were carried out strictly according to regula-
tions of the State Veterinary Authorities of the Cantons of Basel and
Zurich. Female Brown-Norway rats and C57BL/6 mice were obtained
from Charles River (France) and female Harlan Hsd:Npa nu/nu (nude)
athymic mice were obtained from the Novartis breeding stock (Basel,
Switzerland). Rats weighed between 135 and 180 g, whereas mice
weighed between 20 and 30 g before experiments.
Experimental Tumor Models
Five different tumor models were used, all of which have been pre-
viously described in detail [12]. Briefly, two orthotopic syngeneic tumor
models were used: (a) murine B16/BL6 melanoma cells in C57BL/6
mice, where cells injected intradermally in the ear metastasize rapidly
to the lymph nodes of the neck (LN-mets), and (b) rat mammary
BN472 tumors transplanted from donor rats by inoculation of fresh
tumor material in the mammary fat pad. The human tumor cell lines
HCT116 colon, KB31 cervical, and H596 lung were injected sub-
cutaneously (s.c.) in the flanks of athymic nude mice. All models were
used ca. 3 weeks after transplantation or inoculation when tumors
were ca. 100 to 200 mm3 in mice and 200 to 500 mm3 in rats (see indi-
vidual studies).
Tumors were measured by noninvasive PET (see below), or the size
(volume) of all tumors (TVol) was determined using calipers to measure
three orthogonal dimensions and applying the formula: l × h ×w × π / 6.
TVol and animal body weight (BW) measurements were made thrice
per week, just before treatment (baseline), and at the end point.
Compounds/Drugs and Their Application
All compounds used in this study were obtained from the Novartis
Chemistry Research or Pharmaceutical Development. The compounds
and their respective vehicles were prepared each day just before admin-
istration to animals, and the administration volumes were individually
adjusted based on the animal’s BW.
Everolimus (RAD001), anmTOR inhibitor, was obtained as amicro-
emulsion and was freshly diluted in a vehicle of 5% glucose and ad-
ministered by oral gavage (p.o.) to mice daily in a volume 10 ml/kg at
10 mg/kg.
Patupilone (epothilone B, EPO906), a microtubule stabilizer, was
dissolved in polyethylene glycol-300 (PEG-300) and then diluted with
physiological saline (0.9% wt./vol. NaCl) to obtain a mixture of 30%
(vol./vol.) PEG-300 and 70% (vol./vol.) 0.9% saline. Treatment with
vehicle (PEG-300/saline) or patupilone was once weekly using an intra-
venous (i.v.) bolus in the tail vein (2 ml/kg at 0.75 mg/kg) in rats.
PTK/ZK (vatalanib), a pan-VEGF receptor (VEGF-R) inhibitor, was
dissolved in 100% vol./vol. PEG-300 and then diluted 1:1 in 0.9%
saline. Rats received PTK/ZK dosed daily at 100 or 200 mg/kg p.o.
(5 ml/kg).
NVP-AAL881, a dual RAF and KDR (VEGF-R2) inhibitor, was
dissolved in 1 ml of 100% ethanol at a maximum concentration of
25 mg/ml, and then 1 ml of 100% vol./vol. Cremophor EL (Sigma-
Aldrich, Schnelldorf, Germany) was added and vortexed. Finally, 8 ml
of a solution of 5% (vol./vol.) glucose in distilled water was added and
mixed to give 10ml at 2.5mg/ml.NVP-AAL881was dosed at 15mg/kg
p.o. twice daily in rats at 5 ml/kg.
Positron Emission Tomography
FDG was obtained from the commercial production of the Univer-
sity Hospital Zurich (UniversitätsSpital Zürich) with a specific activity
of ca. 1000 GBq/μmol. FLT and FMISO were produced in-house at
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the Department of Radiopharmaceutical Science of the Federal Insti-
tute of Technology of Zurich (Eidgenoessische TechnischeHochschule)
as previously described [13,14]. For both tracers, specific radioactivities
were always higher than 100 GBq/μmol.
PETexperiments were performed as previously reported [12]; tumor
is easily distinguishable from background, and the method is highly
reproducible. Briefly, each tracer (5-45 MBq; 150 μl) was injected
i.v. in nonfasted, restrained animals allowing distribution and accumu-
lation of the radiotracer in the nonanesthetized animal, that is, under
physiological conditions. Injected doses were precisely quantified by
measuring radioactivity in the syringes before and after radiotracer
application. After tracer injection, at 20 minutes for FDG and FLT
or at 80 minutes for FMISO, the animals were anesthetized with iso-
flurane (Abbott, Cham, Switzerland) in an air/oxygenmixture and fixed
on the bed of the scanner. PET experiments were performed using the
dedicated 16-module quad HIDAC tomograph with a submillimeter
resolution (Oxford Positron Systems, Weston-on-the-Green, UK) and
a field of view of 280 mm axially and 170 mm in diameter. PET data
acquisition was initiated 30 minutes (FDG and FLT) or 90 minutes
(FMISO) after radiotracer injection. A warm air stream was used to en-
sure thermostasis at 37°C body temperature, measured by a rectal
probe. Depth of anesthesia was controlled by monitoring respiratory
frequency with a dedicated thorax belt.
Raw data files were acquired in list mode and reconstructed in single
time frame using the OPL-EMalgorithm [12] and a bin size of 0.5 mm.
Reconstruction did not include scatter, random, and attenuation cor-
rection. A simultaneous Na-22 point source measurement was used as
an internal standard to correct the reconstructed data sets for possible
variations in scanner sensitivity. Reconstructed three-dimensional PET
data were evaluated by a region of interest (ROI) analysis using the
dedicated biomedical image quantification software PMOD (Pmod
Technologies Ltd, Adliswil, Switzerland). ROIs were drawn manually
in all coronal slices comprising the tumor, thus providing volume and
the average activity concentration of the entire tumor. For FDG and
FLTstudies, the average activity concentration in the tumor was normal-
ized to the injected dose per BW and expressed as an average standard-
ized uptake value (SUV). For FMISO experiments, ROIs were also
drawn on 5 to 10 subsequent coronal planes containing muscle tissue
at a forelimb. The quantification of FMISO uptake was based on the
tumor-to-muscle retention ratio (TMRR) using muscle tissue as a refer-
ence region, where a TMRR ≥ 1.4 defines the presence of hypoxia [15].
Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Animals were anesthetized using constant inhalation of 1.5% iso-
flurane (Abbott) in a 1:1 mixture of O2/N2 while the animal was lying
on an electrically warmed pad and were cannulated through one lateral
tail vein as previously described [16]. Magnetic resonance imaging
(MRI) experiments were performed on a Bruker DBX 47/30 or Avance
2 spectrometer (Bruker Medical, Fällanden, Switzerland) at 4.7 T
equipped with a self-shielded 12-cm bore gradient system.
For determination of the relative tumor blood volume (rTBV) and
blood flow index (BFI), the iron oxide particle intravascular contrast
agent Endorem (Guerbet, Roissy, France) was injected (6 mmol/kg
of iron). The Endorem uptake curve was fitted with a sigmoid curve
(BioMap based on IDL; Research Systems, Inc, Boulder, CO) to pro-
vide a value for the rTBV (plateau) and the BFI, which was the rTBV
divided by the steepest part of the slope. Values shown in the Results
section are in arbitrary units, and the principles behind measurement
of these parameters have been fully described [16].
For determination of macrophage levels, the contrast agent Sinerem
(Guerbet) was used, which is composed of ultra small particles of iron
oxide (USPIO). The ultra small particles of iron oxide can be internal-
ized by cells of the mononuclear phagocytotic system (including macro-
phages) by absorptive endocytosis and enables tracking of these cells
[17]. For each measuring time point, reference images were acquired
before infusion of 80 μl of Sinerem/100 mg BW and another series
of images 24 hours after infusion of Sinerem. The T2-weighted MRI
signal intensities from the tumor were standardized by comparing to
the signal of a coimaged phantom containing 1 mM MnCl2 solution.
Sinerem causes a decrease in signal intensity, and the extent of this at-
tenuation (percentage) is proportional to the macrophage level.
Experimental Design
When tumors reached the desired size for the study, the tumor-
bearing animals were allocated to different treatment groups, based on
tumor volume, to balance the groups, and various measurements were
made before treatment (baseline), that is, day 0, and at various time
points after treatment. The posttreatment time points were selected as
early (day 2 or 3) and/or late (day 6 or 7 or exceptionally day 14) with the
late time point normally being the end point. At the end of all experi-
ments, animals were killed by CO2 inhalation or decapitation. In some
cases, after the final measurement at the end point, the tumors were ab-
lated and studied by histology and immunohistochemistry (IHC).
Ex Vivo Studies
Histology and IHC were done as previously described [12,18] to de-
termine the number of cells positive for cleaved caspase 3 (apoptosis
marker) or the proliferation markers Ki67 and PCNA. In addition, cells
were scored for the glucose transporter, Glut-1 (RB-9052; Neomarkers,
Fremont, CA).
Macrophages were visualized by immunohistochemical staining with
monoclonal antibody ED1 (Serotec, Düsseldorf, Germany) directed
against rat macrophage lysosomal membrane. Briefly, microwave-
assisted antigen retrieval was carried out for 20minutes in 10mMcitrate
buffer, pH 6.0. After washing in buffered saline, endogenous peroxidase
was quenched with 0.5% H2O2 in methanol for 20 minutes at room
temperature (RT). Nonspecific binding sites were blocked with 10%
normal horse serum for 20 minutes at RT, and the sections were incu-
bated with the primary antibody ED1 diluted 1:100 in 1% normal
horse serum, overnight at RT. Negative controls were incubated with
mouse isotype control (Zymed, San Francisco, CA). After washing in
buffered saline, sections were incubated with biotinylated horse anti–
mouse immunoglobulin G, preabsorbed with rat serum (Vector, Burlin-
game, CA) followed by avidin-biotin horseradish peroxidase complex
(Dako, Glostrup, Denmark). Peroxidase activity was visualized by in-
cubation in a solution of 3.3′-diaminobenzidine tetrahydrochloride
(Medite, Nunningen, Switzerland). Sections were counterstained with
neutral red andmountedwith Pertex (Medite, Nunningen, Switzerland).
For the detection of “free” iron (not phagocytized), macrophages
were first demonstrated by immunohistochemical staining with mono-
clonal antibody ED1, then the Perl Prussian blue reaction was applied
to the slides.
Data Analysis
Results are presented as mean ± SEM except where stated, and all
available data are shown. The effect of a compound on a particular
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parameter, for example, FDG tumor uptake is summarized as the T /C ,
that is, the mean change compared with baseline for drug-treated
animals divided by themean change in treatment for vehicle-treated ani-
mals compared with baseline to provide a T /CFDG as previously de-
scribed [12]. For tumor volume (TVol), BW, and all ex vivo analyses,
differences between groups were analyzed using a t test (for two groups)
or a one-way analysis of variance (ANOVA)withDunnett or Tukey tests
post hoc. For the in vivo biomarker analyses that involved longitudinal
analyses in the same animals, differences were analyzed by (a) two-way
repeated-measures ANOVA and (b) t test or one-way ANOVA as ap-
propriate for each time point; the latter method is therefore associated
with the respective T /C . If necessary, data were normalized by a log10
transformation before statistical analyses. Quantification of the relation-
ship between two parameters was analyzed by the Spearman correlation
to provide the correlation coefficient (r) and the significance (P ). For all
statistical tests, the level of significance was set at P < .05 (two-tailed)
where *P < .05, **P < .01, ***P < .001 versus vehicle.
Results
Effects of Everolimus on FDG uptake by Sensitive Tumors
We have previously characterized the activity of everolimus in cell
culture using 48 different tumor cell lines [3]. On the basis of the
Table 1. Anticancer Activity of Everolimus In Vivo.
Tumor Model IC50 (nM) T /CTVol at the End Point
1 Week 2-3 Week Median
Murine B16/BL6 LN-met 0.7 0.16, 0.27 0.35 0.27
Human H596 5 0.37 0.12, 0.14, 0.35 0.25
Human KB31 1778 0.43 0.32, 0.43 0.43
Human HCT116 4125 0.59 0.33, 0.46, 0.50 0.48
Results show the efficacy of everolimus (T /CTVol) in several different experiments (separated by a
comma) against the different tumor models described in this report, along with the median of the
three to four experiments. Everolimus was always dosed daily at 10 mg/kg p.o. except in two of
the KB31 experiments where 2.5 mg/kg was used (dose-response analyses showed that 2.5 and
10 mg/kg produced equivalent efficacy in this model; see O’Reilly et al. [45]).
Figure 1. Everolimus decreases FDG uptake bymurinemelanoma B16/BL6metastases. Murine B16/BL6 cells were injected intradermally in
the ears of C57BL/6 mice, and after 2 weeks, the lymph node metastases were studied by FDG-PET as described in the Materials and
Methods section, immediately before and 2 days after treatment with everolimus (10 mg/kg p.o.). (A) Representative experiment showing
horizontal head/thorax images of mice with lymph node (red arrow) and primary ear tumors (blue arrow) before and after treatment with
everolimus. (B) Individual SUVs for tumors (n= 10 per treatment group) and the mean ± SEM fractional effect of treatment, where ***P<
.001. (C) Mean ± SEM fractional changes for the effect of vehicle or everolimus on rTBVol, n = 19 per group, and BFI, n = 14 per group.
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concentration inhibiting cell growth by 50% (IC50) for cell prolifera-
tion during 3 days of incubation, cells could be divided into sensitive
(IC50 values of 0.2-65 nM) and insensitive (IC50 values of 150-
4125 nM). One of the cell lines very sensitive to everolimus in vitro
(IC50 = 0.7 nM) were murine B16/BL6 melanoma cells, and when
grown in syngeneic mice, everolimus dose dependently (0.1-10 mg/kg
daily) inhibited growth [2]. For the experiments described in this report,
everolimus was dosed daily at 10 mg/kg (Table 1).
Total uptake of FDG by orthotopic B16/BL6 melanomas in vivo
was strong (mean SUV: 1.75 ± 0.1, n = 10) and relatively homogeneous
in both the primary tumors in the ear and in the lymph node metastases
in the neck (Figure 1A). Daily dosing with everolimus (10 mg/kg) after
2 days caused a marked decrease of FDG uptake in 9 of 10 metastases,
with an overall highly significant (P < .001) decrease in the mean SUV
of 42% from 1.8 ± 0.1 to 1.1 ± 0.1 (Figure 1B). Very similar effects
were detected in the primary tumors. In separate experiments, dynamic
contrast-enhanced magnetic resonance imaging of the LN-mets showed
no effect of everolimus on either rTBVor BFI after 2 days of treatment
(Figure 1C).
The human NSCLC cell line, H596, is also sensitive to everolimus
causing a marked reduction in S-phase after 48 hours (T /C = 0.72) and
inhibiting proliferation in vitrowith an IC50 of 5 nM.When grown as a
s.c. xenograft in athymic nude mice, daily dosing at 10 mg/kg strongly
inhibited growth; T /CTVol after 3 weeks was 0.14 (Figure 2A and
Table 1). As previously reported [12], uptake of FDG by human tumor
xenografts is rather low, and indeed, H596 tumors had a mean SUV
of just 0.23 ± 0.02 (Figure 2B). Nevertheless, two daily doses caused
a significant, albeit small decrease of ca. 20% in the SUV to 0.17 ± 0.01
(Figure 2, B and C). Analysis ex vivo of these tumors on day 2 showed
no significant effects of everolimus on necrosis or staining for caspase 3+
and Ki67+ cells (Figure 2D).
Effects of Everolimus on FDG Uptake by Insensitive Tumors
Human colon HCT116 cells are insensitive to everolimus in vitro
(IC50 = 4 μM), yet daily dosing by the drug (10 mg/kg) could signifi-
cantly inhibit tumor growth after at least 1 week of treatment (Figure 3,
A and B, and Table 1). It is likely that this activity in vivo reflects
the anti–angiogenic/vascular activity of everolimus, which is a potent
inhibitor of cultured human endothelial cells (IC50 = 0.1 nM) and other
stromal cells and decreases tumor microvessel density [2]. Despite this
significant growth inhibition, no changes in FDG uptake were de-
tectable after 2 or 7 days of treatment (Figure 3C), and in a prolonged
experiment, no decrease compared with vehicle was apparent after
2 weeks of treatment (Figure 3D). Similar data were obtained using
Figure 2. Everolimus decreases FDG uptake by human H596 lung tumor xenografts. Human tumors were created by s.c. implantation
of viable H596 tumor tissue in Harlan athymic mice. (A) For efficacy, mice were treated with vehicle or with everolimus (10 mg/kg p.o.)
for 21 days. Results show mean ± SEM. (B and C) A separate cohort of tumor-bearing mice was studied by FDG-PET as described in the
Materials andMethods section, immediately before and 2 days after treatmentwith everolimus. Results show the individual SUVs for tumors
(n=10 per treatment group) and themean± SEM fractional effect of treatment, where *P< .05, **P< .01. (D) Histology and IHC of ablated
tumors on day 2 after completion of the second PET scan.
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the everolimus-insensitive KB31 model (IC50 = 1.8 μM), in which
significant growth inhibition in vivo could be observed (Figure 3E
and Table 1), yet there were no significant changes in FDG uptake rel-
ative to vehicle after 2 or 7 days of treatment (Figure 3F ). In both of
these xenograft models, the basal mean SUV was low at ca. 0.2 and
similar to the H596 model.
Effects of Everolimus on FLT Tumor Uptake
As previously reported [12], uptake of FLT in human tumor xeno-
grafts was less rim-limited than for FDG (Figure 4A) and showed a
higher mean basal SUV. Daily dosing with everolimus after 2 days
caused a significant decrease of 20% in FLT uptake in the sensitive
H596 tumors (Figure 4B), and again in this model, ex vivo analysis
showed no significant effects on necrosis or staining for caspase 3+
and Ki67+ cells (Figure 4C ). At this end point of 2 days, there was a
weak significant correlation between Ki67+ cells and FLT by tumor cells
(r = 0.6, P = .04). Repeat experiments showed similar significant effects
on FLTuptake after 2 days, and another experiment extended to 7 days
showed no evidence of a greater effect with time (Figure W1). This
experiment showed that, also on day 7, there were no significant ef-
fects on necrosis or staining for caspase 3+ or Ki67+ cells, and at the later
end point of 7 days, there was no correlation between FLT and Ki67
(r = 0.13, P = .69). H596 tumors showed strong staining for PCNA
and Glut-1 (>90%), but there was no evidence either that everolimus
affected these parameters after 7 days of treatment (Figure W1).
In the insensitive HCT116 model, everolimus was without signifi-
cant effect on FLT uptake either at day 3 or day 10 after initiation of
daily treatment (Figure 5, A and B). Again, there were no significant
effects on necrosis or percent Ki67+, whereas caspase 3+ staining
showed a trend to increase (Figure 5C ).
Thus, in sensitive models, everolimus rapidly decreased both FDG
and FLT uptake but had no effect on these parameters in insensitive
Figure 3. Everolimus inhibits growthof insensitivehuman tumors but doesnot affect FDGuptake.HumanHCT116 (colon) andKB31 (cervical)
were created by s.c. injection of cells inHarlan athymicmice. In all cases,micewere treated daily p.o.with vehicle or everolimus (10mg/kg). (A
and B) Efficacy in HCT116 tumors for 1 week (A) or 2 weeks (B) showing themean± SEMwith the associated T /CT Vol at the end point. (C and
D) FDG-PET in HCT116 tumors in the respective experiment showing themean fractional change for each treatment comparedwith day 0 (C)
or the individual tumorSUVat twodifferent timepoints (D). (E and F) Efficacy in KB31 tumorswith the fractional change in FDG-PET compared
with day 0 for each treatment, where *P < .05, ***P < .001.
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models despite significant inhibition of tumor growth. In both types of
model, a well-known marker of mTOR inhibition, pS6, was strongly
downregulated [2], but apparently in the insensitive tumors, this was
not transmitted into downstream effects that affect FDG or FLT up-
take. In contrast, everolimus had no effect on the IHC markers of
Ki67 and apoptosis in H596 or HCT116 tumors. Perhaps this is less
surprising given theMoA of everolimus, which is to slow or to block the
G1/S transition rather than to cause cell death [19,20]. Thus, because
Ki67 measures the total number of cycling cells rather than those only
in S-phase, changes in FLTmay not correlate with Ki67 [12,21]. The
MoA of everolimus also includes an important anti–angiogenic/vascular
effect, which involves direct effects on the stroma and indirect effects
through levels of VEGF [2], and this is likely to be responsible for
the growth inhibition seen in vivo. Apparently, however, these stromal
effects did not significantly affect uptake of the radiotracers. These ob-
servations prompted us to investigate the effects of other antiangiogenic
agents in another model that had previously been used to study anti–
angiogenic/vascular agents [22,23] and compare them to the activity of
a cytotoxic.
Effects of Other Compounds on FDG Tumor Uptake
Three other compounds with different MoA were tested for their
ability to affect FDG uptake in a rat orthotopic mammary model,
BN472. This model is well vascularized [22] and shows a good basal
tumor uptake of FDG with a mean SUVof ca. 0.9 [12].
The micotubule stabilizer patupilone strongly inhibited BN472
growth causing tumor stasis (Figure 6A), and this was associated
with a rapid decrease in FDG uptake 2 days after treatment; an effect
Figure 4. Everolimus decreases FLT uptake by human H596 lung tumor xenografts. Human tumors were created by s.c. implantation of
viable H596 tumor tissue in Harlan athymic mice. Tumors were studied by FLT-PET as described in the Materials and Methods section, im-
mediately before and 2 days after treatment with everolimus (10 mg/kg p.o.). (A) Representative experiment showing horizontal whole-body
images of mice with tumors (blue arrow) before and after treatment with everolimus; red arrow indicates the bladder. (B) Individual SUVs for
tumors (n = 6 per treatment group), and the mean ± SEM fractional effect of treatment, where **P< .01. (C) Histology and IHC of ablated
tumors on day 2 after completion of the second PET scan.
270 Effecfs of Everolimus on FDG/FLT Tumor Uptake Honer et al. Translational Oncology Vol. 3, No. 4, 2010
that increased with time (Figure 6B). On day 6, the changes in FDG
correlated positively with the change in TVol (r = 0.49, P = .02), con-
firming this tracer as a good marker of the activity of cytotoxics
(Figure 6C ).
A similarly strong antitumor effect on BN472 tumors was caused
by daily treatment with the dual RAF/KDR (VEGF-R2) inhibitor
NVP-AAL881 (Figure 7A). However, with this compound, there was
no early change in FDG and only a nonsignificant trend for a decrease
in FDG uptake after 7 days (Figure 7B). According to the dynamic
contrast-enhanced magnetic resonance imaging method for detecting
macrophages, which uses ultra small iron particles (Sinerem), NVP-
AAL881 actually decreased macrophage uptake in this model compared
with vehicle at both days 3 and 7 (Figure 7C), suggesting that the ab-
sence of a decrease in FDG uptake was not caused by an influx of gly-
colytic macrophages that can follow chemotherapy [24]. This was
confirmed by IHC at the end point (day 7), showing that iron covered
0.01% to 0.09% of the surface area, with no difference between the two
treatment groups (both 0.04%). Iron was mainly located in mono-
nuclear cells and in fibroblastic areas, with some iron found in the
wall of blood vessels and none in necrotic areas. Double staining with
the Perl Prussian blue reaction and ED1 elucidated the amount of
free, that is, nonphagocytized iron, which showed that 86% was bound
to macrophages with no significant difference between the groups.
Previously, we have shown that the pan-VEGF-R inhibitor, PTK/ZK
(vatalanib) dose-dependently inhibited BN472 growth [23]. Here, daily
dosing with PTK/ZK did not cause tumor regression but still inhib-
ited tumor growth after 7 to 9 days of treatment (Figure 8A), and this
was not associated with any effect on FDG uptake at either day 2 or
day 7 (Figure 8B and FigureW2).On day 9, the tracer FMISOwas used
to assess hypoxia in vivo. This showed that all of the tumors in both
groups were hypoxic (all TMRR > 1.4), and PTK/ZK had no signifi-
cant effect on hypoxia (Figure 8C ). Although the two most hypoxic
tumors had the lowest FDG values, there was no overall significant
correlation between these two parameters (r = −0.22, P = .5, n = 12).
Ex vivo analyses for caspase 3+ staining also showed no effect of the
drug on day 9 (Figure 8D), consistent with previous observations in this
model [18].
Discussion
We have shown that the mTOR inhibitor everolimus can rapidly de-
crease FDG and FLTuptake in solid tumors that had previously been
characterized in vitro as sensitive tumors but that it did not decrease
tracer uptake in tumors characterized as insensitive in vitro such as
HCT116 and KB31. Similar observations have been reported for rapa-
mycin on human tumor xenografts where decreases in FDG and FLT
were linked to changes in hexokinase and thymidine kinase 1 expression
[9]. However, in that report, rapamycin had no effect on the growth of
the insensitive tumors in vivo even after 2 weeks of daily treatment.
Here, and previously [2], we have shown that tumors characterized
Figure 5. Everolimus does not affect FLT uptake by human HCT116 colon tumor xenografts. Human HCT116 tumors were created by s.c.
injection of cells in Harlan athymic mice. (A and B) Tumors were studied by FLT-PET as described in the Materials and Methods section,
immediately before (day 0) and on days 3 and 10 after treatment with vehicle or everolimus (10 mg/kg p.o.). Results show (n = 6 per treat-
ment group) the individual SUVs for tumors (A) and the mean ± SEM fractional effect of treatment (B). (C) Histology and IHC of ablated
tumors on day 10 after completion of the second PET scan.
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as insensitive in vitro can have significantly reduced growth in vivo in
response to everolimus (median T /C = 0.43-0.48), an effect not much
weaker than in the two sensitive tumor models (median T /C = 0.25-
0.27). Such antitumor effects are typical of everolimus monotherapy,
which tends to reduce tumor growth rather than cause regression [3].
These observations on antitumor efficacy, coupled with the demon-
stration that everolimus potently inhibits growth of endothelial and
stromal cells in vitro, reduces VEGF release from tumor cells, and re-
duces tumor vascularization in vivo [2], suggest that inhibition of
growth of HCT116 and KB31 tumors probably includes a substantial
antiangiogenic/vascular action. Surprisingly, however, the growth in-
hibitory effect on HCT116 or KB31 in vivo could not be detected by
changes in uptake of FDG and FLT, suggesting that, for some reason,
these PET tracers cannot detect an antiangiogenic MoA. This is an
important observation because the clinical effects of everolimus mono-
therapy are also characterized by stable disease rather than by partial
or complete response, that is, tumor growth inhibition rather than
regression [4].
These observations prompted us to compare the effect of other com-
pounds that have antiangiogenic or cytotoxic action mechanisms on
FDG uptake using an orthotopic mammary model: BN472. The
BN472 model has been previously characterized as well vascularized,
and both cytotoxic and antiangiogenic compounds can inhibit its
growth [22,23,25]. Unfortunately, this model is not derived from a cell
line, and thus, the in vitro sensitivity of everolimus could not be as-
sessed, although experiments in vivo showed weak inhibition after
2 weeks of treatment suggesting an everolimus-insensitive tumor cell
[25]. In the BN472 model, the microtubule stabilizer patupilone de-
creased FDG uptake at both early (day 2) and late time points (day 6)
while causing tumor stasis. In contrast, NVP-AAL881, a compound
that inhibits both RAF and the VEGF-R2 (KDR), failed to affect FDG
uptake in the BN472 tumors despite causing tumor regression. The
pan-VEGF-R inhibitor, PTK/ZK, also failed to reduce FDG uptake
significantly despite inhibiting the growth of these tumors. Although
these results are puzzling, there are several possible explanations that
may contribute to this phenomenon. These include 1) increases in
TBF and permeability affecting FDG and nutrient delivery, 2) a stress
response by the tumor cell aiming to avoid apoptosis by increasing
transport of various nutrients including glucose and thymidine, 3) de-
creases in plasma glucose causing a relative increase in the levels of
FDG, 4) induction of hypoxia leading to stimulation of glycolysis
through HIF-1, and 5) increases in the number of glycolytic macro-
phages that infiltrate the tumor [24,26–30].
Where the mechanism for FDG uptake has been studied, investiga-
tions demonstrate that the rate-limiting step is at FDG phosphorylation
by hexokinase rather than FDG transport by glucose transporters such
as Glut-1 [9,31,32]. This suggests that changes in TBF are unlikely to
affect FDG uptake except perhaps under conditions where TBF is very
low, for example, in human tumor xenografts [12]. However, evero-
limus has been shown to decrease TBF [33,34], and in the B16/BL6
model described here, we could find no effect at all on the parameter
BFI, which is equivalent to TBF. Consequently, we reason that al-
though we did not measure TBF in the xenograft models, it is unlikely
that an everolimus-induced increase in TBF in the insensitive models,
Figure 6. Patupilone inhibits growth and FDG uptake by rat mammary BN472 tumors. Rat BN472 tumors were created by transplantation
of viable tissue into the mammary fat pad and, after 2 weeks, were treated once with vehicle or patupilone (0.7 mg/kg i.v.). Results show
the mean ± SEM for (A) efficacy (n = 12 per group) and (B) fractional change in FDG uptake compared with day 0 (n = 11 per group),
where *P < .05, **P < .01, ***P < .001. (C) Pearson correlation between the fractional change in FDG uptake and the change in tumor
volume (T Vol) at the end point of day 6 compared with day 0.
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for example, through normalization [35], can explain the effects observed
here. Furthermore, despite a low FDG SUV, the fact that Glut-1 levels
were very high in the H596 xenograft (and were unaffected by everoli-
mus treatment) is also suggestive that nutrient supply is not rate-limiting
for FDG uptake. There was no evidence that everolimus caused apop-
tosis in the mouse models, and thus, a stress response of increased glu-
cose or thymidine uptake (thus veiling a decrease in FDG or FLT
uptake) is also unlikely to explain the effects we observed. Further-
more, everolimus tends to slightly increase plasma glucose levels [4]
(and unpublished observations), which might cause a decrease in
FDG uptake, although where the influence of plasma glucose has been
reported [36–38], this is of the order of 10-fold increases in plasma
glucose. Thus, small changes in plasma glucose are unlikely to affect
our observations on FDGuptake. Hypoxia can be positively correlated
with glycolysis, but this is not always the case [30], and we did not ob-
serve it in the BN472 model where there was also no effect of the anti-
angiogenic PTK/ZK on hypoxia, which might have veiled a decrease
in FDG uptake. Finally, an influx of glycolytic macrophages after cell
kill could also veil a decrease in FDG uptake. We did not measure
macrophages in the xenograft experiments but, at least in the rat
BN472 model, an increase in tumor macrophage content seemed
not to be an explanation for NVP-AAL881 because macrophage levels
were actually decreased as measured by a contrast-enhanced MRI
method, and IHC indicated no change compared with vehicle.
Thus, taken all together, our results suggest that anti–angiogenic/
vascular inhibition of tumor growth does not affect tumor uptake of
FDG or FLT as measured by PET in vivo. This may be considered a
surprising observation, and further clinical confirmation of this hy-
pothesis is important. A small FDG-PET study of eight patients with
NSCLC showed that everolimus induced FDG changes ranging from
−72% to +34%, but correlations with patient outcome or investigations
of antiangiogenic effects were not made [10]. Another report from phase
1/2 studies showed that FDG changes in response to rapamycin were
unrelated to tumor response by RECIST [11]. We are not aware of
any clinical FDG/FLT-PET studies with PTK/ZK or NVP-AAL881,
and data for other agents broadly described as antiangiogenic are
minimal [39]. The multikinase inhibitor sunitinib has been shown to
significantly reduce FDG-PET in some, but not all, patients with gas-
trointestinal stromal tumors, and generally, there was a strong correla-
tion between progression-free survival and the early FDG-PETresponse
in this indication [40]. However, this drug has a strong potency against
cellular c-KIT and PDGF-R equaling that against VEGF-R2 [41–43],
and thus, its activity is not limited to the stromal compartment of
the solid tumor. Interestingly, the eponymous antiangiogenic agent,
bevacizumab, when tested for clinical activity against tumor blood vol-
ume, flow, permeability, interstitial fluid pressure and FDG in a six
patients, induced rapid changes in all but FDG, which only changed,
if at all, after 3 months of treatment [44].
In conclusion, we have shown that the allosteric mTOR inhibitor
everolimus can significantly decrease FDG and FLTuptake by tumors
in mice that are inherently sensitive to the drug. However, in less sen-
sitive models where anti–angiogenic/vascular mechanisms probably
predominate, no effect on these tracers could be detected. In a ratmodel,
antiangiogenics also failed to affect FDG uptake. These data suggest
Figure 7. Effects of NVP-AAL881 on ratmammary BN472 tumors. Rat BN472 tumorswere created by transplantation of viable tissue into the
mammary fat pad and, after 2 weeks, were treated twice daily with vehicle or NVP-AAL881 (15 mg/kg p.o.). Results show the mean ± SEM
(n= 6 per group) for (A) efficacy and (B) fractional change in FDG uptake compared with day 0, where ***P< .001. (C) A separate cohort of
treated rats showing the relative Sinerem concentration (compared with day 0) in each tumor determined on day 3 and day 7 after treatment
initiation. Rats were injected i.v. with Sinerem (8 μl/kg) 24 hours before measurements as described in the Materials and Methods section.
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that FDG/FLT-PETmay provide false-negatives for anti–angiogenic/
vascular inhibition and, consequently, may not be suitable as early-
response markers for everolimus, other rapalogs, or pure antiangiogenic
agents. Thus, although positive PETresponses are always useful, negative
PET responses for rapalogs and antiangiogenics would preclude PET
being used to obtain an OBD. These conclusions warrant clinical testing.
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Figure W1. Effects of everolimus on human H596 lung tumors. Human H596 NSCLC tumor xenografts in athymic mice were treated daily
with vehicle or everolimus (10 mg/kg p.o.) for 1 week, and FLT uptake was quantified as described in the Materials and Methods section on
days 2 and 7. Results show the fractional change in FLT uptake on days 2 and 7 comparedwith day 0,where **P< .01.Micewere culled, and
the ablated tumors were analyzed by histology and IHC for the percentage of necrosis, PCNA, Ki67, caspase 3, and Glut-1. A representative
tumor slice shows very strong staining for Glut-1 (>90% cells), and there was no evidence that this was affected by everolimus treatment.
Figure W2. PTK/ZK does not affect FDG uptake by rat mammary
BN472 tumors. Rat mammary BN472 tumors grown orthotopically
in BN rats were treated daily with vehicle or PTK/ZK (100 mg/kg
p.o.), and FDG uptake was quantified as described in the Materials
and Methods section on days 2 and 7. Results show the changes
in FDGuptake in individual tumors (n=6per group) and the fractional
change in FDG uptake on days 2 and 7 compared with day 0.
